Enasidenib , 97% , 1446502-11-9
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB423.20 | In Stock |
|
| 10mg | RMB759.20 | In Stock |
|
| 25mg | RMB1695.20 | In Stock |
|
| 50mg | RMB3055.20 | In Stock |
|
| 100MG | RMB5031.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 168-170°C |
| Boiling point: | 581.0±60.0 °C(Predicted) |
| Density | 1.477±0.06 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | Soluble in DMSO (up to 25 mg/ml) |
| form | solid |
| pka | 14.70±0.29(Predicted) |
| color | White |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| InChIKey | DYLUUSLLRIQKOE-UHFFFAOYSA-N |
| SMILES | C(NC1=NC(C2=NC(C(F)(F)F)=CC=C2)=NC(NC2C=CN=C(C(F)(F)F)C=2)=N1)C(C)(O)C |
Description and Uses
Enasidenib (1446502-11-9) is a potent (IC50’s = 100 nM IDH2R140Q homodimer, 30 nM IDH2R140Q/WT heterodimer and 10 nM IDH2R172K/WT heterodimer) and selective inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).1? It suppressed the production of the oncometabolite (R)-2-Hydroxyglutarate (a competitive inhibitor of αKG-dependent dioxygenases which leads to epigenetic dysregulation) and induced cellular differentiation in primary human IDH2 mutation-positive acute myeloid leukemia cells.1,2? Recently approved for clinical use by the FDA.
Enasidenib is a first-in-class oral selective inhibitor of mutant IDH2 enzymes (isocitrate dehydrogenase 2), for the treatment of adults with relapsed or refractory IDH2-mutated acute myeloid leukemia.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P280-P305+P351+P338 |
